Avacta and Daewoong form cell and gene therapies JV
UK-based Avacta Group (AIM: AVCT) and Korean pharma Daewoong Pharmaceutical (KSX: 069620) are to form a joint venture (JV) aimed at developing cell and gene therapies incorporating the Cambridge-based company’s Affimer proteins.
Mesenchymal stem cells (MSC) are promising agents for autoimmune and inflammatory diseases. The JV will develop a new class of MSCs that are primed to produce Affimer proteins, which will enhance the immune-modulatory effect when administered to patients, by reducing inflammatory or autoimmune responses.
Off-the-shelf products planned
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze